The Team

Rationale

Two complementary founders: Nikhil brings domain expertise in longevity science and health-tech entrepreneurship through Healome; Matthew brings the full-stack engineering and ML execution that built the entire platform. Together they cover the science AND the product.

Talking Points

• "Nikhil founded Healome One — a computational biology platform for tissue-specific aging models. He brings deep domain expertise in longevity science and the health data infrastructure that underpins Syntropy's Health Graph."
• "Matthew brings the biochemistry and biotechnology foundation (Penn State BME), transitioned through health-tech applied ML research (CMU Computational Biology, aging clocks at Healome), and now builds AI agent systems. He worked as a collaborative engineer at Healome alongside Nikhil before building Syntropy's entire platform."
• "The team covers both sides: Nikhil owns the health science and business strategy; Matthew owns the product and engineering. Protocol adherence uses pharmaceutical-grade PDC methodology — not growth hacking."
• "AI tooling as a force multiplier: the team ships at velocity equivalent to a 5-person team. Capital-efficient execution from day one."
• "With funding, next hires are a senior engineer to scale the Health Graph infrastructure and a Head of Growth to scale the outreach engine."
• Transition: "Let me show you why this is defensible."

Anticipated QA

• Q: How do the founders divide responsibilities?
  A: Nikhil leads business strategy, health science direction, and partner relationships — leveraging his Healome network. Matthew leads product, engineering, and GTM execution — he built the entire platform and outreach engine.
• Q: What is Healome?
  A: Healome One is a computational biology company focused on tissue-specific aging models and biomarker research. Nikhil founded it. The domain expertise in longevity science directly informs Syntropy's Health Graph and protocol design methodology.
• Q: Two-person team is still lean. How do you mitigate?
  A: Three ways. First, the product is already built — this de-risks technical execution. Second, AI tooling gives us 5-person-team velocity. Third, the first hires with funding are a senior engineer and Head of Growth. The risk is scaling, not capability.
• Q: What is Matthew's computational biology background?
  A: Carnegie Mellon MS in Computational Biology, Penn State BS in Biomedical Engineering. Research in aging clocks and biomarker extraction. That is why Protocol Adherence Rate uses pharmaceutical-grade PDC methodology rather than simple streak counting.

Sources

• Healome One — computational biology platform (Nikhil Yadala, Founder)
• Platform built and deployed on Vercel, Cloudflare Workers, and Shopify Partners
• AI-augmented development: Claude Code, Cursor — measurable velocity increase documented in commit history